JP2006505525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505525A5 JP2006505525A5 JP2004529472A JP2004529472A JP2006505525A5 JP 2006505525 A5 JP2006505525 A5 JP 2006505525A5 JP 2004529472 A JP2004529472 A JP 2004529472A JP 2004529472 A JP2004529472 A JP 2004529472A JP 2006505525 A5 JP2006505525 A5 JP 2006505525A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- optionally substituted
- hydrogen
- cyclopentyl
- diol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- -1 2-hydroxycyclopentyl Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- SSYDTHANSGMJTP-UHFFFAOYSA-N oxolane-3,4-diol Chemical compound OC1COCC1O SSYDTHANSGMJTP-UHFFFAOYSA-N 0.000 claims 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 230000003243 anti-lipolytic effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40371202P | 2002-08-15 | 2002-08-15 | |
| US45009403P | 2003-02-25 | 2003-02-25 | |
| PCT/US2003/025629 WO2004016635A2 (en) | 2002-08-15 | 2003-08-15 | Partial and full agonists of a1 adenosine receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505525A JP2006505525A (ja) | 2006-02-16 |
| JP2006505525A5 true JP2006505525A5 (https=) | 2006-08-17 |
| JP4596913B2 JP4596913B2 (ja) | 2010-12-15 |
Family
ID=31891396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004529472A Expired - Fee Related JP4596913B2 (ja) | 2002-08-15 | 2003-08-15 | Ａ１アデノシン受容体の部分および完全アゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7022681B2 (https=) |
| EP (1) | EP1537133B1 (https=) |
| JP (1) | JP4596913B2 (https=) |
| KR (1) | KR20050067384A (https=) |
| CN (1) | CN100480255C (https=) |
| AT (1) | ATE368048T1 (https=) |
| AU (1) | AU2003263846B2 (https=) |
| CA (1) | CA2495370A1 (https=) |
| DE (1) | DE60315164T2 (https=) |
| ES (1) | ES2288632T3 (https=) |
| MX (1) | MXPA05001844A (https=) |
| NO (1) | NO20051296L (https=) |
| NZ (1) | NZ538590A (https=) |
| RU (1) | RU2340623C2 (https=) |
| WO (1) | WO2004016635A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
| WO2008143667A1 (en) * | 2007-05-17 | 2008-11-27 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| WO2013062943A1 (en) * | 2011-10-24 | 2013-05-02 | Glaxosmithkline Intellectual Property Development Limited | New compounds |
| MX2017010844A (es) * | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| JP6643719B2 (ja) * | 2016-05-31 | 2020-02-12 | セントラル硝子株式会社 | ３，３，３−トリフルオロプロパノールの製造方法 |
| CN115232054A (zh) * | 2021-04-22 | 2022-10-25 | 山东新时代药业有限公司 | 一种7-乙基色醇中间体化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1254888A (en) * | 1984-10-26 | 1989-05-30 | Bharat Trivedi | N.sup.6-bicycloadenosines |
| USRE36494E (en) * | 1990-02-20 | 2000-01-11 | Discovery Therapeutics, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5140015A (en) * | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5278150A (en) * | 1992-04-24 | 1994-01-11 | Whitby Research, Inc. | 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5589467A (en) * | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| AU4377397A (en) * | 1996-10-14 | 1998-05-11 | Novo Nordisk A/S | Novel therapeutically active adenosine derivatives |
| GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
-
2003
- 2003-08-15 WO PCT/US2003/025629 patent/WO2004016635A2/en not_active Ceased
- 2003-08-15 ES ES03788541T patent/ES2288632T3/es not_active Expired - Lifetime
- 2003-08-15 EP EP03788541A patent/EP1537133B1/en not_active Expired - Lifetime
- 2003-08-15 CN CNB038193612A patent/CN100480255C/zh not_active Expired - Fee Related
- 2003-08-15 CA CA002495370A patent/CA2495370A1/en not_active Abandoned
- 2003-08-15 JP JP2004529472A patent/JP4596913B2/ja not_active Expired - Fee Related
- 2003-08-15 MX MXPA05001844A patent/MXPA05001844A/es active IP Right Grant
- 2003-08-15 RU RU2005106997/04A patent/RU2340623C2/ru not_active IP Right Cessation
- 2003-08-15 US US10/641,930 patent/US7022681B2/en not_active Expired - Fee Related
- 2003-08-15 AT AT03788541T patent/ATE368048T1/de not_active IP Right Cessation
- 2003-08-15 NZ NZ538590A patent/NZ538590A/en not_active IP Right Cessation
- 2003-08-15 DE DE60315164T patent/DE60315164T2/de not_active Expired - Lifetime
- 2003-08-15 AU AU2003263846A patent/AU2003263846B2/en not_active Ceased
- 2003-08-15 KR KR1020057002587A patent/KR20050067384A/ko not_active Ceased
-
2005
- 2005-03-14 NO NO20051296A patent/NO20051296L/no not_active Application Discontinuation
-
2006
- 2006-02-15 US US11/355,656 patent/US20060135467A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527502A5 (https=) | ||
| CA2476683A1 (en) | Partial and full agonists of a1 adenosine receptors | |
| CN105814019B (zh) | 脲衍生物、或其药理学上所容许的盐 | |
| JP4021195B2 (ja) | 部分もしくは完全ａ１アゴニスト：ｎ６複素環式５′−チオ置換アデノシン誘導体 | |
| JP4492968B2 (ja) | １−チオ−ｄ−グルシトール誘導体 | |
| JP5194588B2 (ja) | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 | |
| JP2008518904A5 (https=) | ||
| HK1044953A1 (zh) | C-吡唑a2a受體激動劑 | |
| RU2009127781A (ru) | Производные аденозина в качестве частичных и полных агонистов а1 аденозиновых рецепторов | |
| CN1155608C (zh) | 炔丙基苯基醚a2a受体激动剂 | |
| TWI620746B (zh) | 新醫藥化合物、包含該化合物之醫藥組成物及其用途 | |
| CN1407971A (zh) | 取代的2－硫代－3,5－二氰基－4－芳基－6－氨基吡啶及其应用 | |
| EP3036221B1 (en) | Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b | |
| KR20150013198A (ko) | 카테콜 o-메틸트랜스퍼라제 활성 억제 화합물 | |
| EP3274340B1 (en) | Inhibitors of hepatitis c virus polymerase | |
| CN108350016A (zh) | 抗病毒四氢呋喃衍生物 | |
| JP2006505525A5 (https=) | ||
| JP2008540683A5 (https=) | ||
| WO2016015638A1 (zh) | 丙型肝炎病毒抑制剂及其应用 | |
| RU2005106997A (ru) | Частичные и полные агонисты аденозиновых рецепторов а1 | |
| JP2006516641A5 (https=) | ||
| JP2010513489A5 (https=) | ||
| KR100463694B1 (ko) | 티오펜 ａ2ａ 수용체 작용제 | |
| CN103304555A (zh) | 一组苯-噁唑基衍生物及其制备方法和作为impdh抑制剂的相关应用 | |
| JP2008540685A (ja) | Ａ１アデノシンレセプターアゴニスト |